Research Updates
Elamipretide and Reproductive Ageing: What a 2026 Oocyte Study Reports
A 2026 Aging Cell study reports laboratory and mouse findings on elamipretide, oocyte quality and reproductive ageing, with clear preclinical limits.
Retatrutide TRIUMPH-1: 80-Week Phase 3 Findings
What a new 80-week phase 3 trial reported about retatrutide, body weight, knee osteoarthritis and obstructive sleep apnoea.
Retatrutide in TRIUMPH-2: 80-Week Phase 3 Results
What the TRIUMPH-2 phase 3 trial reported about retatrutide in adults with obesity and type 2 diabetes, including weight change and safety findings.
GLP-1 Receptor Agonists: 44 Adolescent Records
GLP-1 receptor agonists were not linked to higher short-term suicidality scores in a small retrospective review of 44 adolescents.
Tirzepatide vs Semaglutide: 8,176 Asthma Pairs
Tirzepatide and semaglutide had similar recorded asthma-exacerbation risk in 8,176 matched pairs, while SABA use differed modestly.
Tirzepatide and Cold: No Added Loss in Mice
Tirzepatide and intermittent cold exposure improved separate measures in obese mice, but the combination did not add weight loss.
Tirzepatide in IBD: 3,042 Matched Pairs
Tirzepatide in IBD was associated with fewer IV steroid events in 3,042 matched pairs, but the retrospective design cannot establish cause.
Nanocarriers of 4 to 30 nm Cut Fat, Not Food Intake
Nanocarriers delivering an anti-inflammatory drug to fat tissue reduced body fat in obese mice with no change in how much the animals ate.
Tirzepatide in HFpEF: LV Mass Down 12.4 g at 6 Months
The International Journal of Cardiology published a prospective cohort study online on 8 September 2026 by Karanxha, Guni, Xhabija, Ded...
Tirzepatide 15 mg: 1.60 kg of Fat-Free Mass Lost
Tirzepatide 15 mg cut fat-free mass by 1.60 kg in a meta-analysis of 19 trials, where laboratory screening found risk the trial reports missed.